Retinal Vasculitis After Syfovre Injections: Etiology is Still Unknown and Incidence Rate Remains Unclear   (Posted by Tom Lamb at Drug Injury Watch)   Syfovre (pegcetacoplan) was approved by the FDA in February 2023 as an eye injection to treat geographic atrophy (GA), a relatively rare condition secondary to age-related macular degeneration. Beginning in April 2023, there have been reports of Syfovre eye injury cases, including (1) retinal vasculitis resulting in significant vision loss, and (2) intraocular inflammation without retinal vascular involvement. Syfovre e ..read more

Pre-Existing Allergy Toward Polyethylene Glycol (PEG) is Most Recent Causation Theory Offered by Apellis   (Posted by Tom Lamb at Drug Injury Watch)   In late January 2024, a leading medical journal for ophthalmologists and retina specialists, the Journal of VitreoRetinal Diseases, published this Syfovre case report, "Occlusive Retinal Vasculitis After a Single Injection of Pegcetacoplan", written by three authors affiliated with the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, in Miami, Florida. Here is the A ..read more

Research Finding: Semaglutide Increased the Risk of Deep Vein Thrombosis (DVT) by 266% in Patients with Type 2 Diabetes   (Posted by Tom Lamb at Drug Injury Watch)   Semaglutide-containing drugs that are being used for weight loss purposes include Ozempic, Rybelsus, and Wegovy. Somewhat hidden in a relatively recent medical journal article is the mention of a blood clots side effect of semaglutide weight-loss drugs like Ozempic, deep vein thrombosis (DVT). Remarkably, medical researchers found that semaglutide increased the risk of deep vein thrombosis by 266% when doi ..read more

Learn About Related Symptoms and Diagnosis Process for Gastroparesis, a Side Effect of Ozempic, Wegovy, Rybelsus, and Trulicity   (Posted by Tom Lamb at Drug Injury Watch)   In this article, we present some gastroparesis case reports involving the use of GLP-1 receptor agonists semaglutide (e.g., Ozempic, Wegovy, Rybelsus) or dulaglutide (e.g., Trulicity) that have been published recently by medical journals. These gastroparesis case reports discuss specific patient profiles, related symptoms, and the diagnosis process for gastroparesis, a side effect of Ozempic, Wegov ..read more

Prolia "Black Box" Warning: Harm From Severe Hypocalcemia Ranges From Hospitalization For Life-threatening Events to Death   (Posted by Tom Lamb at Drug Injury Watch)   A January 2024 JAMA Original Investigation article, "Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent Patients", in summary, presents evidence of a Prolia increased risk of hypocalcemia in patients with chronic kidney disease (CKD) that can be 40 times more than bisphosphonate pills. From the "Key Points" beginning of this online JAMA article about Prolia and severe hypocalcemia ..read more

November 2023 Syfovre Label Change Comes After Earlier Reports of Eye Inflammation and Severe Vision Loss   (Posted by Tom Lamb at Drug Injury Watch)   We have been writing about Syfovre drug safety developments having to do with retinal vasculitis cases and other eye-related side effects since July 2023. This latest article is about the November 2023 Syfovre label change that adds new warnings about retinal vasculitis and/or retinal vascular occlusion associated with Syfovre injections. For background, here is a general Syfovre timeline bringing us up to the present t ..read more

A Syfovre Case of Hemorrhagic Occlusive Vasculitis-type Inflammation With Continued Blindness Is Reported   (Posted by Tom Lamb at Drug Injury Watch)   At the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO), various Syfovre patients eye side effects cases were discussed by William J. Johnson, M.D., of the Wolfe Clinic in Iowa. These Syfovre side effects cases range from hemorrhagic occlusive vasculitis-type inflammation with continued blindness to uveitis to vision loss to symptomatic floaters. From this November 3, 2023 news report, "Details on 5 Ca ..read more

Researchers Compared Semaglutide Drugs, Such as Ozempic and Wegovy, to Contrave, a Non-GLP-1 Drug, in Weight-Loss Patients   (Posted by Tom Lamb at Drug Injury Watch)   An October 2023 medical journal article presented the results of a recent study comparing patients who used two different types of weight-loss drugs to see whether drugs containing the GLP-1 semaglutide showed Ozempic and Wegovy associated with gastroparesis, a gastrointestinal condition also referred to as stomach paralysis. Even those two Novo Nordisk drugs, Ozempic and Wegovy, each have semaglutide a ..read more

Paralytic Ileus, the Slowing of Food Movement Through Digestive System, is Similar to Intestinal Obstruction   (Posted by Tom Lamb at Drug Injury Watch)   In September 2023 the Ozempic (semaglutide) drug label was updated to inform doctors and patients that adverse reaction reports concerning ileus, a gastrointestinal disorder, have been received for semaglutide during the time since Ozempic was first approved by the FDA in 2017. This September 2023 Ozempic label change can be found in part "6.3 Postmarketing Experience" of the Ozempic Full Prescribing Information docu ..read more

Severe Gastric Side Effects Include Stomach Paralysis, Gastroparesis, And Intestinal Blockages   (Posted by Tom Lamb at Drug Injury Watch)   Ozempic is an increasingly popular drug for the treatment of diabetes which is used "off-label" for weight loss, also. Wegovy is a higher-dose version of Ozempic that is FDA-approved to treat obesity. Both of these relatively new drugs, from the pharmaceutical company Novo Nordisk, contain the active ingredient semaglutide. In the several years since being on the market, there have been an increasing number of so-called "semagluti ..read more